Research
Hormonal
Adjuvant GLP-1RA users achieved a higher mean proportion of days covered (PDC) of 74.30% compared to 66.91% for SGA-only users.
Incorporating GLP-1RA may enhance medication adherence in patients prescribed SGAs.
StrongSupportsmedium confidence
adjuvant GLP-1-RA users achieved a higher mean proportion of days covered (PDC; 74.30% vs 66.91%)
Why this rating
Based on the retrospective cohort study design with a large sample size.
Source
Impact of Adjuvant GLP-1RA Treatment on the Adherence of Second-Generation Antipsychotics in Nondiabetic Adults
Jerusha Daggolu et al. · Journal of Clinical Psychopharmacology · 2026
DOI 10.1097/jcp.0000000000002145
cohort · n=2940
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →